Results 121 to 130 of about 5,560 (153)
Some of the next articles are maybe not open access.
Aprepitant Alleviates Poststroke Pneumonia in a Mouse Model of Middle Cerebral Artery Occlusion
Rejuvenation ResearchElevated substance P can be utilized to predict early mortality during the first week of cerebral infarction. Whether aprepitant, a substance P receptor blocker could be utilized to alleviate poststroke pneumonia which is investigated in this study ...
Zhihui Xie +3 more
semanticscholar +1 more source
Comparisons of aprepitant and ondansetron
American Journal of Health-System Pharmacy, 2007We are responding to the letter from Cavaretta and Noviasky[1][1] concerning Merck’s two Phase III studies of aprepitant 40 mg p.o. versus ondansetron 4 mg (as the hydrochloride salt) i.v. in the prevention of postoperative nausea and vomiting (PONV).[2][2],[3][3] Prophylactic ondansetron ...
Alexandra, Carides +4 more
openaire +2 more sources
Aprepitant for Erlotinib-Induced Pruritus
New England Journal of Medicine, 2010To the Editor: Aprepitant is the first commercially available drug of a new class of neurokinin-1–receptor antagonists for treating chemotherapy-induced nausea and vomiting. The dominant ligand for the neurokinin-1 receptor is substance P.1,2 An increase in the number of neurokinin-1 receptors on keratinocytes has been found in patients with chronic ...
Vincenzi B, Tonini G, Santini D
openaire +3 more sources
Aprepitant – a novel NK1-receptor antagonist
Expert Opinion on Pharmacotherapy, 2003Recently, a new class of agents, the substance P antagonists, has heralded a novel approach for the control of emesis. Aprepitant (Emend, Merck & Co., Inc.), the first of this class, was recently approved by the FDA for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV).
Lisa, Patel, Celeste, Lindley
openaire +2 more sources
Naunyn-Schmiedeberg's Archives of Pharmacology, 2023
S. Akbari +4 more
semanticscholar +1 more source
S. Akbari +4 more
semanticscholar +1 more source